Zobrazeno 1 - 10
of 58
pro vyhledávání: '"Ralph Reid"'
Autor:
Wei Chen, Thomas A Waldmann, Anusara Daenthanasanmak, Sigrid P Dubois, Jürgen R Müller, John A Hangasky, Ralph Reid, Daniel V Santi
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 1 (2022)
Externí odkaz:
https://doaj.org/article/ed308cd4754b429b9c2a44c2b53607f8
Autor:
Daniel V. Santi, Gary W. Ashley, Ralph Reid, Brian R. Hearn, Henry F. VanBrocklin, Shaun D. Fontaine, Denis R. Beckford Vera
Synthetic procedures and supplementary data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55b4d95813ac8d15d0aa6c8aeafa6b03
https://doi.org/10.1158/1535-7163.22520635.v1
https://doi.org/10.1158/1535-7163.22520635.v1
Autor:
Daniel V. Santi, Gary W. Ashley, Ralph Reid, Brian R. Hearn, Henry F. VanBrocklin, Shaun D. Fontaine, Denis R. Beckford Vera
The goal was to develop and characterize a companion diagnostic for the releasable PEG40kDa∼SN-38 oncology drug, PLX038, that would identify tumors susceptible to high accumulation of PLX038. PEG conjugates of the zirconium ligand desferroxamine B
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::526260949562b037552d54b4a520d6c1
https://doi.org/10.1158/1535-7163.c.6542710.v1
https://doi.org/10.1158/1535-7163.c.6542710.v1
Publikováno v:
Proceedings of the National Academy of Sciences. 119
The C-natriuretic peptide (CNP) analog vosoritide has recently been approved for treatment of achondroplasia in children. However, the regimen requires daily subcutaneous injections in pediatric patients over multiple years. The present work sought t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c4dbcb8cda9d5e43d4e1f3632245c6d
https://doi.org/10.1073/pnas.2201067119
https://doi.org/10.1073/pnas.2201067119
Autor:
John A Hangasky, Wei Chen, Sigrid P Dubois, Anusara Daenthanasanmak, Jürgen R Müller, Ralph Reid, Thomas A Waldmann, Daniel V Santi
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 1 (2022)
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 1 (2022)
BackgroundInterleukin-15 (IL-15) is an important cytokine necessary for proliferation and maintenance of natural killer (NK) and CD8+ T cells, and with great promise as an immuno-oncology therapeutic. However, IL-15 has a very short half-life and a s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c428e32448239c514bcdc49d163a841
http://europepmc.org/articles/PMC8804710
http://europepmc.org/articles/PMC8804710
Publikováno v:
Cancer Chemotherapy and Pharmacology. 84:729-738
Optimal efficacy of a macromolecular prodrug requires balancing the rate of drug release with the rate of prodrug elimination. Since circulating macromolecules have different elimination rates in different species, a prodrug optimal for one species w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f405c5737a17f425aec6ed5b9ac2ca27
https://doi.org/10.1007/s00280-019-03903-5
https://doi.org/10.1007/s00280-019-03903-5
Autor:
Denis R. Beckford Vera, Ralph Reid, Henry F. VanBrocklin, Brian R. Hearn, Daniel V. Santi, Shaun D. Fontaine, Gary W. Ashley
Publikováno v:
Molecular cancer therapeutics. 19(2)
The goal was to develop and characterize a companion diagnostic for the releasable PEG40kDa∼SN-38 oncology drug, PLX038, that would identify tumors susceptible to high accumulation of PLX038. PEG conjugates of the zirconium ligand desferroxamine B
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aadaadac773d1cc60d9ba2e81e80f7a7
https://pubmed.ncbi.nlm.nih.gov/31744896
https://pubmed.ncbi.nlm.nih.gov/31744896
Autor:
Angelo D Santi, Philip C. Smith, Daniel V. Santi, Gary W. Ashley, Ralph Reid, Shaun D. Fontaine
Publikováno v:
Cancer chemotherapy and pharmacology. 85(1)
The purpose of this study was to determine the importance of UGT1A1 activity on the metabolism and pharmacokinetics of a releasable PEG ~ SN-38 conjugate, PLX038A. Irinotecan (CPT-11) is converted to the topoisomerase 1 inhibitor SN-38 by first-pass
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::363bdd205e5cdcd2fdbc7612cf17e9a7
https://pubmed.ncbi.nlm.nih.gov/31707444
https://pubmed.ncbi.nlm.nih.gov/31707444
Publikováno v:
Bioconjugate Chemistry. 27:1638-1644
We developed a long-acting drug-delivery system that supports subcutaneous administration of the peptidic somatostatin agonist octreotide-a blockbuster drug used to treat acromegaly and neuroendocrine tumors. The current once-a-month polymer-encapsul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba3cf8b39d4767964c96be64f80b52c5
https://doi.org/10.1021/acs.bioconjchem.6b00188
https://doi.org/10.1021/acs.bioconjchem.6b00188
Autor:
Daniel V. Santi, David G. Parkes, Eric L. Schneider, Ralph Reid, Thomas A. Lutz, Gary W. Ashley
Publikováno v:
Domestic animal endocrinology. 70
There is growing evidence that peptidic glucagon-like peptide-1 receptor agonists (GLP-1RA), such as exenatide, may provide useful therapeutic options for treatment of feline diabetes. However, because such drugs are administered subcutaneously, it i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e7c7d2a7cd6fab40a159036f2e941ad
https://pubmed.ncbi.nlm.nih.gov/31479925
https://pubmed.ncbi.nlm.nih.gov/31479925